Find Clinical Trial

The efficacy and safety of trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention ATPCI study. An international, multicentre, randomised, double-blind, placebo-controlled study in patients treated for 2 to 4 years.


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationCoronary Artery Disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

TRIMETAZIDINE,
S006790

Active Substance CodeS006790
Protocol CodeCL3-06790-010
EudraCT Code2010-022134-89


Documents and links

Lay summary
Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility